ERA-EDTA登记:欧洲透析与肾移植患者COVID-19死亡率高
基于ERA-EDTA登记数据,纳入2020年2月至4月欧洲7国4298例肾替代治疗患者,采用倾向评分匹配历史对照计算COVID-19归因死亡率。透析患者28天死亡率为20.0%(95%CI 18.7%-21.4%),移植受者为19.9%(17.5%-22.5%);移植受者死亡风险是匹配透析患者的1.28倍(1.02-1.60)。
要点
- 透析患者COVID-19 28天归因死亡率为20.0%,移植受者为19.9%。
- 移植受者死亡风险较匹配透析患者高28%(RR 1.28,95%CI 1.02-1.60)。
- ≥75岁移植受者COVID-19死亡率达44.3%,老年及男性透析患者风险更高。
核心结论
- COVID-19大流行对欧洲肾替代治疗患者造成显著死亡负担,透析与移植受者28天归因死亡率均约20%。
- 移植受者死亡风险高于匹配透析患者,高龄移植受者死亡率尤高。
研究设计与样本
- 基于ERA-EDTA登记的多国回顾性队列,收集2020年2月1日至4月30日欧洲7国4298例肾替代治疗患者数据。
- 采用倾向评分匹配历史对照数据计算COVID-19归因死亡率,随访28天。
主要发现
- 透析患者(n=3285)28天COVID-19归因死亡率为20.0%(95%CI 18.7%-21.4%)。
- 移植受者(n=1013)28天COVID-19归因死亡率为19.9%(95%CI 17.5%-22.5%)。
- 各国间COVID-19死亡率存在差异,老年肾替代治疗患者及男性透析患者死亡风险增加。
- ≥75岁移植受者中44.3%(95%CI 35.7%-53.9%)未存活。
- 移植受者死亡风险为匹配透析患者的1.28倍(95%CI 1.02-1.60)。
临床怎么用
- 应将透析和移植受者视为COVID-19高危人群,加强防护与早期干预。
- 对高龄移植受者及男性透析患者需重点关注死亡风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19-attributable mortality was calculated using propensity score-matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%-21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%-22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%-53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02-1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
引用
- Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020. PMID: 32979369. doi:10.1016/j.kint.2020.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。